Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies
Authors:
Open Access
- 2 August 2023
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0288285
Abstract
Background: The life quality of about two-thirds of patients with COVID-19 is affected by related olfactory dysfunctions. The negative impact of olfactory dysfunction ranged from the decreased pleasure of eating to impaired quality of life. This research aimed to provide a comprehensive understanding of the effects of corticosteroid treatments by comparing that to other currently available treatments and interventions. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist’s 27-point checklist was used to conduct this review. PubMed (Public/Publisher MEDLINE), PubMed Central and EMBASE (Excerpta Medica Database) databases were conveniently selected and Boolean search commands were used for a comprehensive literature search. Five core search terms were "effects of treatments", " COVID-19-related olfactory dysfunction", "corticosteroids", "treatments" and "interventions". The reporting qualities of the included studies were appraised using JBI (Joanna Briggs Institute) appraisal tools. The characteristics of the 21 experimental studies with a total sample (of 130,550) were aggregated using frequencies and percentages and presented descriptively. The main interventions and their effects on the duration of the COVID-19-related olfactory dysfunction were narratively analyzed. Results: Among patients with COVID-19, the normal functions of the olfactory lobe were about 23 days earlier to gain with the treatments of fluticasone and triamcinolone acetonide nasal spray compared with that of mometasone furoate nasal spray and oral corticosteroid. The smell loss duration was reduced by fluticasone and triamcinolone acetonide nasal spray 9 days earlier than the inflawell syrup and 16 days earlier than the lavender syrup. The nasal spray of corticosteroids ended the COVID-19-related smell loss symptoms 2 days earlier than the zinc supplementation, about 47 days earlier than carbamazepine treatment and was more effective than palmitoylethanolamide (PEA) and luteolin and omega-3 supplementations and olfactory training. Treatment with oral corticosteroid plus olfactory training significantly improved Threshold, Discrimination and Identification (TDI) scores compared with olfactory training alone. A full dose of the COVID-19 vaccination was not uncertain to reduce the COVID-19-related smell loss duration. Conclusion: Corticosteroid treatment is effective in reducing the duration of COVID-19-related smell loss and olfactory training, the basic, essential and effective intervention, should be used as a combination therapy.Keywords
This publication has 59 references indexed in Scilit:
- In Ear Surgeries Intravenous Dexamethasone Preoperatively Decreases Post Operative Sore Throat After Endotracheal Intubation in Adult Patients: A Prospective Randomized Control StudyIndian Journal of Otolaryngology and Head & Neck Surgery, 2020
- Olfactory dysfunction revisited: a reappraisal of work-related olfactory dysfunction caused by chemicalsJournal of Occupational Medicine and Toxicology, 2018
- Depression, Olfaction, and Quality of Life: A Mutual RelationshipBrain Sciences, 2018
- Anosmia—A Clinical ReviewChemical Senses, 2017
- Pharmacologic treatment for postviral olfactory dysfunction: a systematic reviewInternational Forum of Allergy & Rhinology, 2016
- The role of surgery in the management of phantosmiaThe Laryngoscope, 2015
- Hidden consequences of olfactory dysfunction: a patient report seriesBMC Ear, Nose and Throat Disorders, 2013
- Learning about the Functions of the Olfactory System from People without a Sense of SmellPLOS ONE, 2012
- Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthmaActa Oto-Laryngologica, 2011
- Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo biloba, and Mometasone Nasal SprayJAMA Otolaryngology–Head & Neck Surgery, 2009